Pharmaceutical patents in the Trans-Pacific Partnership. The more things change the more they stay the same? by Cano Pérez, Rubén
																																				
	
	
 
FACULTY OF LAW 
LAW DEGREE 
FINAL DEGREE PROJECT 
ACADEMIC COURSE: 2016-2017 
 
 
TITLE: 
PHARMACEUTICAL PATENTS IN THE TRANS-PACIFIC 
PARTNERSHIP. THE MORE THINGS CHANGE THE MORE THEY 
STAY THE SAME? 
 
 
 
AUTHOR: 
D. Rubén CANO PÉREZ 
 
ACADEMIC SUPERVISOR: 
DR. D. Manuel DESANTES REAL 
	
	
	
	
Final Degree Project                                           Author: Rubén CANO PÉREZ 
Law and Business Administration Degree                            Academic Supervisor: Manuel DESANTES REAL 
1	
	
 
ABSTRACT: Life is most value heritage that human beings we have. Pharmaceutical 
patents play a fundamental roll in the development of people’s survival of different 
countries, which as it is known does not have the same advantage level, extending the 
lapse of time that the generic medicaments take to be into the market. The Trans-Pacific 
Partnership Agreement includes this subject in his acquis, therefore we will try to 
analyse if the global protection changes under the applicable juridical structure 
umbrella.	
 
RESUMEN: La vida es el patrimonio más valioso que tenemos los seres humanos. Las 
patentes farmacéuticas juegan un papel fundamental en el desarrollo de la supervivencia 
de los habitantes de diferentes países, que como bien sabemos no tienen el mismo nivel 
de avance, alargando el lapso de tiempo que los genéricos tardan en llegar al mercado . 
El Acuerdo Transpacífico de Cooperación Económica incluye ésta materia entre su 
acervo, por lo que intentaremos analizar si la protección global cambia bajo el paraguas 
del marco jurídico vigente. 
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INTRODUCTION  
	
1. Globalization is the economic, technological, social and cultural process on a 
world wide scale that consists in the growing communication and independence 
amongst the different countries. Furthermore, it is the trend of markets and enterprises 
to spread, achieving a global dimension that exceeds the drawn outlined national 
borders. In earlier times, the Bretton Woods Agreements, established in 1944, the 
framework for international commerce and finance, created the World Bank, and the 
International Monetary Fund. Later, the GATT appears, General Agreement on Tariffs 
and Trade, beginning the international relations control. Likewise, 40 years later the 
implementation of the World Bank and the International Monetary Fund, the 
negotiation for the origin of World Trade Organisation starts, ending in 1994. In the 
intermediate years, two significant events take place: the signing of the North American 
Free Trade Agreement (NAFTA), in 1988; and the Warsaw Pact, which was going to 
put an end to Cold War in 1991, and definitely to give the starting signal to the 
globalisation after the falling of communism. Since that moment, the integration of 
local economies translates in market economy, that brings extraordinary progress, but 
also numerous risks. 
 
2. Ending in 1994, and administered by the World Trade Organization, the 
Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) appeared, 
setting up the minimum standards for the adequate protection of intellectual property 
rights, as the own TRIPS pointed out. The TRIPS recognized among others, the 
applicability of the basic principles of GATT 1994, the provision of adequate standards 
and principles concerning the availability, scope and use of trade-related intellectual 
property rights taking into account differences in national legal systems1. A point as 
important as conflictive was at the time the access to essential medicines, which even 
nowadays is source of many controversies, bringing us to the key aspect of this paper.   
 
3. Starting from the AIDS 2  in Africa, TRIPS has been subject of several 
modifications on this topic, in which pharmaceutical patents play a decisive role. From 
																																								 																				
1 TRIPS, Part 1, General Provisions and Basic Principles. 
2 Acquired Immune Deficiency Syndrome 
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that vision, I will analyse how the “Agreement of the XXI century” will change the 
protection standard of the pharmaceutical patents and consequently, which would be the 
results for different economies. To do this, in the first part, I will put you in the context, 
showing out the magnitude of the agreement through the mover reasons of the 
agreement, and a brief conclusion. 
 
4. As you must know, people don’t have the same opportunities to gain access to 
the pharmaceutical products. TPP implementation in countries that have different 
development levels, and consequently, don’t have the same capacity to access to the 
medicines could produce that the measurements which could be adapted to developed 
countries, impede the entry of the drugs to countries with a low development level 
because of the tardive appearance of the generics. What I will try to do in the second 
part of this paper is go over the principal steps for the generic drugs to access into the 
market, highlighting the general and specific regulation, which bring us to the main 
conflictive points in my opinion according to the Trans Pacific Partnership: life cycle 
of a pharmaceutical product, protection of undisclosed test or other data, and treatment 
of the generics. 
 
5. Therefore, “Does the Trans-Pacific Partnership Agreement change, in an 
extraordinary way, the possibilities for developing countries and least developed 
countries to access pharmaceutical products?”  
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EMERGENCE OF THE TPP 
 
6. Not long ago, was the Doha’s Round council meeting, in November 2001, Qatar. 
The aim was to confirm the process of integration, concluding the work started at the 
Uruguay’s Round, and trying to promote completely the liberalisation of international 
trade, definitively, a multilateral trade system. The objective it seemed clear, a system 
that it could include international trade rules for all countries, for all markets. 
 
 
7. Perhaps, at the birth’s moment of the Doha Development Program negotiation, 
as it is known colloquially, and still previously with the Uruguay’s Round, no-one had 
thought in a change of scene. No-one noticed that the states, instead of losing power in a 
progressive manner, would be gaining it, taking a main roll separately. The slow 
evolution of the negotiations and the indefinite suspension in 2006, even though it 
where unblocked at Bali’s Conference at 2013, produced the proliferation of bilateral, 
under-regional, and regional agreements across the length and breadth of the world. 
Two of the most important: The Trans Pacific Partnership Agreement (TPP), and the 
Transatlantic Trade and Investment Partnership (TTIP). Consequently, the failure of 
Doha’s Round, and the shortage of cooperation structures (specially in Oriental Asia), 
makes even more important the achievement of stable economic and commercial 
mechanisms for cooperation that, through the common progress, dissolve 
inflexibilities3. With that perspective, bearing in mind as much the economic dynamism 
of Asia, as the geopolitical tensions that in this continent we can observe, we must 
analyse the dynamic of regional and commercial integration. 
 
 
 
 
 
 
																																								 																				
3 	GRYNSPAN. R., “ El nuevo reequilibrio global”, XXI Reunión Primaria del Círculo de 
Montevideo, Universidad de Alicante, 16 Octubre 2016.  
( vid. http://circulodemontevideo.org/XXI-Reunion-Plenaria.asp ) 
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8. Moreover, about what was said before and the universal context, we can affirm 
that the Trans-Pacific Partnership Agreement (TPP), emerge fundamentally of two 
main events. One the one hand, the weakening of WTO as a guide of prices and good 
exchange rules, translated in the failure of Doha’s Round4. On the other hand, the 
impossibility of the Mechanism of Cooperation Asia Pacific (APEC) to reach the Bogor 
Goals at 2010. 
 
9. The purpose of the TPP, is to redesign the trade, economical, political and 
juridical relations, within the nations of Asia-Pacific zone. It is in that moment, where 
the system breaks down, making place to a structural change of international commerce, 
that makes us wonder: Where, where are we going? Are we heading to a multilateral 
structure? Who are the actors, all countries? Or on the contrary, are we on the blocky 
structure way? If actually, we are heading to a blocky structure, how will it be? Are they 
going to obey to the historical order (geographic), or they will change their orientation 
towards geopolitics?5 I dare myself to assert, that we are in the second case, blocks 
which obey to the geopolitical position of countries. It is quite clear, it is not a secret, 
the transfer of power among north and south, and west and east of the globe of the 
world, taking place a change of paradigm without precedents. With the unitary system 
offside, we realize ourselves that the globalisation, at the same time we were thinking 
was approaching us, is moving us away, fragmenting us. Consequently, we are not 
facing an era change, but a change of era. Here it is where we can place the main key of 
the international commerce architecture, which is called “the framework of 21st 
century” and which could be an inflexion point in the international relationships, as 
many privates as publics.   
 
 
 
 
																																								 																				
4 	BARTESAGHI, I., “Efectos del TPP en Asia-Pacífico y Latinoamérica”, Foreign Affairs 
Latinoamérica, Vol.15: Num. 3, pp 43-45, México, 2015.  
(vid.http://www.observatorioasiapacifico.org/data/OBSERVATORIO.Images/Publication/temp/
2015100101511512_Bartesaghi_49.pdf)	
5 Vid. 3. 
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THE AGREEMENT’S MAGNITUDE 
 
10. The Trans Pacific Strategic Economic Partnership Agreement (TPP) or simply 
Trans Pacific Agreement, is a free trade pact among several countries of the Pacific Rim 
that tackles a variety of subjects. Because of his amplitude, that is reflexed in its 30 
chapters; its clandestinity; and the predictable economic repercussion that it is going to 
have at the relations of this century; it has been as criticized as praised around the 
world.  
 
 
Rising and parties 
 
11. Since the 90’s decade, Asia has taken a turning point in their trade policy. At 
2010, it existed 61 trade agreements concludes, of which 47 where operatives and 25 
concerned to the Asia Pacific zone. The origin of the agreement is regional in nature. At 
2002, in the bosom of the Asia-Pacific Economic Cooperation (APEC), Los Cabos 
(Baja California), three countries as Singapore, New Zealand and Chile, began the 
negotiations with regard to their economic association. The fit had to be later the Pacific 
Three Closer Economic Partnership (P3 CEP), that only pretended “closer economic 
relations” between mentioned countries. Later, the pact was formalized at 2003, and it 
began counting with the interest of other countries like Brunei Darussalam, that will add 
at 2005, setting the Trans Pacific Strategic Economic Agreement (P4), which was 
operative at 2006.6 
 
12. At 2008, the White House heard about the treaty, and Washington began to see 
up the pact, handled by George Bush president, U.S. included himself into the 
negotiations, specially at investments and financial services. Barack Obama, the 
president-elect at 2009 endorse this decision of turning over the trade centre to the other 
side of the planet, leaving Europe out borders. Since that moment, U.S. led the 
negotiations, and the agreements passed to the international first scene, attracting the 
attention of numerous actors that up to this moment were not being interested. After, all 
the agreement affairs will be highly confidential. Besides the U.S. inclusion into the 
																																								 																				
6 	OROPEZA GARCÍA, A. : «El Acuerdo de Asociación Transpacífico (TPP) ¿Bisagra o 
confrontación entre el Atlántico y el Pacífico? », p. 13, UNAM, México, D.F., 2013	
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negotiations, because of motives we will explain posteriorly, the pact changes totally of 
sphere passing from a simple agreement, that reunite four “non-powerful” economies, to 
the legal structure which we can appreciate today, treating several subjects in an 
extraordinary way. Australia, Peru and Viet-Nam, would be included into the 
negotiations in 2008. Malaysia, was to do later, at October 2010. At the same month, 
but at 2012, Mexico and Canada would incorporate. For the circle’s closure, in July 
2013 would take place the Japan’s inclusion.7 
 
 
 
Country Agreement Inclusion into the TPP 
negotiations 
Singapore P3 CEP/ P4/ TPP 2002 
New Zealand P3 CEP/ P4/ TPP 2002 
Chile P3 CEP/ P4/ TPP 2002 
Brunei Darussalam P4/ TPP 2005 
UU.EE. TPP 2008 
Australia TPP 2008 
Peru TPP 2008 
Viet-Nam TPP 2008 
Malaysia TPP 2010 
México TPP 2012 
Canada TPP 2012 
Japan TPP 2011 
Data source: Compiled on the basis of information provided by Vid. 2.8 
 
 
 
 
 
 
																																								 																				
7 Vid. 6.  
8 Graphic: own production. 
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What is the Trans-Pacific Economic Cooperation Agreement about? 
 
13. Already analysed the parties of the pact, the subject is divided in two 
fundamental parts: the tax reduction and the creation of common regulation within the 
implicated economies. The subjects, regarding the chapters, are as follows: 
 
 
02.National treatment and market 
access for goods 
16.Competition policy 
03.Rules of origin and origin procedures 17.State-owned enterprises and 
designate monopolies 
04.Textiles and apparel 18.Intellectual property 
05.Custom administration and trade 
facilitation  
19.Labour 
06.Trade remedies 20.Environment 
07.Sanitary and phytosanitary measures 21.Cooperation and capacity building 
08.Technical barriers to trade  22.Competitiveness and business 
facilitation 
09.Investment 23.Development 
10.Cross-border trade in services 24.Small and medium-sized enterprises 
11.Financial services 25.Regulatory Coherence 
12.Temporary entry for business 
personal 
26.Transparency and anti-corruption 
13.Telecommuncations 27.Administrative and institutional 
provisions 
14.Electronic commerce 28.Dispute settlement 
15. Government procurement  
 Data source: Compiled on the basis of information provided by Vid. 2.9 
 
 
																																								 																				
9 Graphic: own production. 
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Therefore, it is a formal third generation free trade agreement, who includes goods and 
services, origin rules, formulas for settlement disputes, sanitary and phytosanitary 
measures, intellectual property, public works supply and competition policies, as a 
reduction of more than 18.000 taxes. The TPP, has as a main additional characteristic, 
the existence of bilateral and sub-regional trade agreements, as well as the intention to 
keep them. Or what is the same thing, the present agreements will coexist with the TPP 
as well as 1.2. article of the chapter about initial provisions and general definitions says. 
Without any aim to be exhaustive, the pact is looking to enclose a general framework 
for their, each party, intern implementation. Who is not an obstacle for particularities 
that can emerge imperatively. Of the foreseen on the legal text and having the general 
context under regard, we can extract that the agreement heads to a future development 
of opportunities and challenges, as well as a likely union of other economies which 
operates on this zone reinforcing the regional economies integration and founding a free 
trade area in the Asia-Pacific zone. 
 
14. With mention to the TPP preamble, we can draw that the parties commit 
themselves to stablish a regional agreement promoting the economic integration for the 
trade and investment liberalization, resulting directly the economic increase as well as 
many welfares.  At the same time, the aim is to create new opportunities for the workers 
and entrepreneurs, contributing to the implementation of the living standards, the 
consumers’ benefits, reducing poverty and promoting sustainable growth. Therefore, the 
pact searches to reinforce the friendly bows and cooperation among them and the 
parties’ territory people, under the rights, obligations and principles declared at the 
Marrakesh Agreement, creating the World Trade Organization (WTO). As well, 
recognizes the parties’ right to regulate and resolve with relation to the establishment of 
a framework and regulation of priorities, to preserve the flexibility, saving the public 
welfare, the environment, and the existent resources until the moment. 
 
15. However, despite the extraordinary delay of the agreement’s object and the 
numerous benefits that could emerge, the main thing is that reunites 40% good’s trade 
economy. Concretely, 37,5% of world’s production. Those twelve countries make 11% 
world population, which could be translated in 800 million people. Other information is, 
that it supposes: 23% world exports, 27% imports, 32% incomings of direct foreign 
investments, and 42% of outputs. In numbers, noting that the benefits could be reduced 
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at the beginning, from 2025 the TPP track would be a raising of 104 billion dollars per 
year on social benefits. Here it is the main point, because reuniting a high percentage of 
the international trade, there are outside, partially, the control of any market unification 
organism as the WTO is. This is due to two groups under the subject’s regard: a) those 
known as WTO-plus, already existing at the WTO, of which there are concluded 
agreements among three or more WTO members, and his scope can be bigger or smaller 
than the WTO regulation; and b) those known as WTO-extra, which are agreements not 
regulated by the WTO, but can be developed apart from the organization10. 
 
16. Consequently, in general, the TPP is an agreement type WTO-plus, who goes 
beyond what WTO’s multilateral trade system envisioned. The range of subjects, that is 
not only largest, but that the reach of integration is stricter and deeper, including, of 
course: agriculture sector, services liberalization, investment protection, competition 
policies, consumer’s protection, settlement disputes, clauses of workers and 
environmental protection and stipulations to assure the regulatory coherence between 
the parties, as well as more protection to the intellectual property (especially 
pharmaceutical patents).  
 
 
The TPP and the United States 
 
17. Besides the Doha’s Round failure and the stagnation of APEC11, as well as the 
non accomplishment of the Bogor Goals to 2010, the agreements takes real importance 
since the U.S. inclusion into the negotiations. It is clear that facing the passivity, or 
impossibility of the WTO to fix a uniform market, they had to emerge regional 
integration agreements. It is here, where the principal economical and political powers 
play his roll. 
 
18. Thus, the pact is very important under a geopolitical vision, because U.S. search 
directly moderate the China’s power in the Asia-Pacific zone, and consequently, in the 
																																								 																				
10  WTO (OMC): Programa de Políticas Comerciales y Gobernanza del Centre for Socio-
Economic Development (CSEND), Sesión 29: ”Plurilateralismo o multilateralismo Punto de 
vista de múltiples colectivos interesados”, INT/SUB/3451, Jakarta, Septiembre de 2015. 
11 Asia-Pacific Econonomic Cooperation. 
Final Degree Project                                           Author: Rubén CANO PÉREZ 
Law and Business Administration Degree                            Academic Supervisor: Manuel DESANTES REAL 
12	
	
main environment in which it is envisioned the economic development of 21th century. 
Revealing is the declaration of Barack Obama, affirming that “when 95% potential U.S. 
consumers lives abroad, doesn’t makes sense that China write trade rules”. The reality 
is that after the second part of 20th century has been a present power in Oriental Asia 
and Oceania on: finance, economy, military, transport, political and cultural life affairs. 
This century faces the apparition of China, no longer as an ideological and systemic 
rival of bipolarism and Cold War, but as a stronger competitor that U.S. never had. As 
an increasing power, U.S. search contain China, but trying to benefit of his enormous 
economic, scientific and political dynamic.12 
 
19. Because of that and the high confidentiality a lot of theories had emerged 
regarding this agreement since the high confidentiality has not allowed the main 
interested performers in knowing the particularities or the different proposals that were 
on the table, that is, its advance. The data privacy, like we were noting before, has 
caused a chain of speculations linked to the U.S.  political interests of leading an 
integration structure of a geopolitical zone that since the Chinese economic exit, has 
been living a deeper economic and politic transformation. Regarding that treaty from 
this perspective many doubts arise on whether the parties, or U.S. as the leader of the 
negotiations, are taking into account the different developments between countries, the 
institutional capacities, and the political and legal systems of every country being part 
of the agreement. If it is not like that, it will emerge an extraordinary problem for some 
of involved countries, because I have to remember that we are facing a WTO-plus 
agreement. 
 
 
Conclusion 
 
20. All in all, the Trans-Pacific Partnership Agreement, could have several 
consequences or objectives: a) to create a modern and comprehensive track for the 
agreements that could take place since now in an international level; b) a deeper 
promotion of the global integration in the Asia-Pacific zone; c) the consolidation of 
																																								 																				
12 	PETRI, P., PLUMMER, M., ZHAI, F. «The Trans-Pacific Partnership and Asia-Pacific 
Integration: A Quantitative Assessment», pags 43-46, East-West Center, Honolulu, 2011. 
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existent trade agreements (around 14 bilateral or regional treaties within the parties at 
TPP); and d) the TPP would increase, mainly but not only, the U.S. exports to the 
Asiatic market, because numerous regional agreements excluded that country before.13 
 
21. Though TPP in a strict manner is not an APEC initiative, it is considered part of 
the search of pathfinders to transform this mechanism of intergovernmental 
conferences, in a true Free Trade Area at Asia-Pacific (FTAAP). The TPP, 
consequently, could be the precursor of FTAAP, and also could be the potential start of 
a new regional and global regulation system, but with the U.S. in its hearth. Evidence of 
this is the sign of the declaration in which the Association of Southeast Asian Nations 
(ASEAN) members proclaim a single market in Kuala Lumpur the 22 November 2015. 
The association is formed by Myanmar, Brunei, Cambodia, Philippines, Indonesia, 
Laos, Malaysia, Singapore, Thailand and Viet-Nam, with a total of 630 million people, 
with an economic combined export of 2,6 trillion dollars. Therefore, the TPP should not 
to be seen as a trade-legal component, but make amply the perspective thinking it will 
generate multitude of extra contractual consequences to the directly involved parties as 
well as the other Pacific Rim countries, not to mention with the results that will have in 
the future for the rest of the international relations.14 Results that will be materialized 
also in the sanitary system of the signers’ people, in the everyday lives of the 
individuals pertaining to least developed countries. 
  
 
 
 
 
 
 
 
 
																																								 																				
13	NIÑO PÉREZ, I. :  «China ante el Tratado de Asociación Transpacífico (TPP): Riesgos, 
alternativas y oportunidades», pags. 2-5,  México, 2013.	
14 Vid. 5 
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WHEN PUBLIC HEALTH IS ON THE TABLE 
 
22. Health, perhaps, is the most important personal good linked to our own life as 
human beings and something we have in our heritage, because time is ephemeral and 
life is finite, and health can’t be bought (at least directly). Definitively, here is where the 
pharmaceutical patent’s problem resides. So then, what is the problem? The situation 
arises from decades ago, if not centuries, where people died if they had not enough 
resources. Their resources were insufficient to pay the price of certain medicines, so the 
least developed population, or if we want poorest population, suddenly could not reach 
these type of products. Governments of developing countries have attempted to improve 
access to essential medicines by taking various measures, which reduce the price of 
drugs, but they have faced extreme pressure from developed countries and from the 
multinational pharmaceutical industry based on the current system of global 
pharmaceutical patent protection. In accordance with that, the Global Health 
Observatory (pertaining to the World Health Organization) says, among 1.4 and 1.7 
million people died in 2015 due to human immunodeficiency virus (HIV) and acquired 
immunodeficiency syndrome (AIDS), which is a consequence of an inability to access 
to medicines and its limitations. With this pharmaceutical patent system, there has been 
an attempt to establish a balance, in which after a monopolistic exploitation throughout 
an extensive time period, the biological product information became public, and allows 
the “generics” to be introduced into the market. Or as WTO affirms, “achieve a balance 
between the social goal in long term to offer incentives for inventions and future 
creations, and as a short term goal to allow the use of existent inventions and 
creations”. In this way, simplified, although the market entry is often though, the 
investment in resources is protected generating new sanitary advantages, and if not 
protected, they will not be achieved. Obviously, it should be a balance but, are we on 
balance? Where is balance mentioned? Are twenty years of protection enough for a 
piece of information (under sanitary and a public interest) that could be vital for a 
country’s population?   
 
23. The greatest disadvantages emerge when there are different countries with 
different development speeds, generating a higher price of pharmaceutical products in 
developed countries, and in developing countries with relatively small commercial 
markets and low levels of disposable income there is very little incentive for 
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pharmaceutical companies to conduct extensive research and development to create 
drugs for life-threatening diseases. Here, consequently, to evaluate the regulation we 
must refer ourselves to the Trans Pacific Partnership and the Doha’s Declaration on 
the TRIPS Agreement and Public Health15 which was adopted the 20 November of 
2001, with preference as art. 18.6 from TPP asserts. Together with what was said 
earlier, we must insert this analysis into the juridical segment dedicated to patents 
within Intellectual Property, among which each party according to article 18.7 
undertakes, having ratified: a) Patent Cooperation Treaty; b) Paris Convention for the 
Protection of Industrial Property. Likewise, each party is obliged to add (if they are not 
party already) to: c) Berne Convention for the Protection of Literary and Artistic Works; 
d) Madrid Protocol concerning the International Registration of Marks; e) Budapest 
Treaty on the International Recognition of the Deposit of microorganisms for the 
Purposes of Patent Procedure; f) Singapore Treaty on the Law of Trademarks; g) 
International Convention for the Protection of New Varieties of Plants (UPOV 1991); 
h) WIPO Copyright Treaty (WCT); i) WIPO Performances and Phonograms Treaty 
(WPPT). Therefore, we can appreciate that TPP Agreement brings a global, common 
and legal structure to all signatory countries.     
 
24. Taking into account what was said before, I will try to analyse the damages and 
benefits of the agreement linked to the pharmaceutical patents that differ between 
countries and their level of development, and attempt to answer the main question under 
study: Does the Trans-Pacific Partnership Agreement change, in an extraordinary way, 
the possibilities for developing countries and least developed countries to access 
pharmaceutical products? To answer this question, I will analyse pharmaceutical 
patents regulation highlighting which I consider the key points, and pass over the 
disadvantages of the TPP.  
 
 
 
 
 
 
 
																																								 																				
15 Vid. https://www.wto.org/spanish/tratop_s/trips_s/pharma_ato186_s.htm 
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PHARMACEUTICAL PATENTS, GLOBAL AND SPECIFIC 
REGULATION 
 
25. As the TPP defines in art. 18.52, a new pharmaceutical product means a new 
medicine that doesn’t contains or use a chemical entity that has been previously 
recognised in a party’s territory. 
 
26. Patentable subject matter. Under the structure of the Agreement on Trade-
Related Aspects of Intellectual Property Rights (TRIPS), the engagements about 
patentable subject matter set themselves up in article 18.37 of TPP, with the following 
as main points: 1) patents must be available for any invention, whether a product or 
process, in all fields of technology, provided that the invention is new, involves an 
inventive step and is capable of industrial application; 2) patents must also be available 
for inventions claimed as at least one of the following: new uses of a known product; 
new methods of using a known product; or new processes of using a known product; 3) 
parties are permitted, should they so desire, to exclude from patentability inventions that 
may offend order public or morality, including to protect human, animal or plant life or 
health or to avoid serious damage to nature or the environment; and 4) arties are also 
permitted to exclude: 4.a) diagnostic, therapeutic and surgical methods for the treatment 
of humans or animals; 4.b) and animals other than microorganisms, and essentially 
biological processes for the production of plants or animal, other than non biological 
and microbiological processes, and plants. In this topic, compared with TRIPS 
regulation (art. 27), we can find more than other, one innovation or implementation 
among all highlighted points. Point 2, which we were talking about, is an extension of 
the obligations under TRIPS, that although if it is true that the implementation is 
allowed in some juridical systems, some others parties will have to include this precept, 
so that could be one leiv-motiv for international issues. On other hand, with point 4.b). I 
don’t think that it will suppose any problem as far as most of this regulation is already 
regarded at UPOV 9116. 
 
27. Grace period. Here we have another innovation from the TPP regarding TRIPS. 
Grace period, introduced in article 18.38, makes a novelty for new countries that are 
																																								 																				
16 International Convention for the Protection of New Varieties of Plants. 1991. 
Final Degree Project                                           Author: Rubén CANO PÉREZ 
Law and Business Administration Degree                            Academic Supervisor: Manuel DESANTES REAL 
17	
	
signing the agreement, as are Japan and New Zealand; however, not for countries like 
Mexico, United States or Canada, that already have this figure in their internal law. In 
this system, each party shall refuse information provided in public divulgations to 
determine if one invention is a novelty or has an inventive activity, and also if the public 
divulgation was:  1) made by the patent applicant or a person that obtains the 
information in a direct way or indirectly from the applicant; b) or if it took place in the 
previous months 12 before the application deadline of a party’s territory. During this 
period, it brings the applicants a general immunity to face up likely consequences via 
“self-disclosure” of the invention before requesting the patent, which is not anticipated 
in the TRIPS. 
  
28. Patents revocation. Specified in article 18.39, there is not any difference or 
novelty regarding the rules applied before the TPP, therefore allowing countries to 
introduce any revocation cause as long as it continues respecting 5th article of the Paris 
Convention and the TRIPS Agreement.  
 
29. Exceptions. As well, article 18.40 allows the introduction of likely exceptions, 
which I don’t think it is going to suppose a big controversy, as it doesn’t go beyond the 
standards established up to the moment. 
 
30. Other use without authorization of the right holder. In a similar manner we can 
analyse article 18.41, whose drafting reiterates directly which article 31 of the TRIPS 
Agreement says. The article considers obligatory licences as part of the general 
objective of the agreement, which is to settle up a balance among the promotion of 
access to the existing pharmaceutical products, and promoting investment and 
development of new medicines. The TRIPS, doesn’t have a specific enumeration of 
causes, but article 31 (in relation with our TPP article) refers to circumstances of 
national emergency, circumstances of extreme urgency and anticompetitive practices17. 
A matter of extraordinary relevance is the “imports under obligatory licences according 
to the art. 31, f) TRIPS”. Those obligatory licences are used mainly to provide for their 
																																								 																				
17 ANDERSON, A.: «Global Pharmaceutical Patent Law in Developing Countries- Amending 
TRIPS to Promote Access for All», The Berkeley Electronic Press, Tulsa, 2006. 
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internal market, and allow countries to import, generic medicines cheaper with the 
obligatory licences in case that they are not able to make it by themselves. It includes, as 
well, measures to prevent the pharmaceutical products flow to inappropriate markets 
and other rules that receiving governments within the system have to implement to keep 
all others members informed. To the concern of signer countries of the TPP: Australia, 
Canada, U.S., Japan, New Zealand announced voluntarily that they will not use this 
system as an importing member; and Mexico and Singapore declared that they only 
would use the system as importers when presented by a situation of national emergency 
or extreme urgency.  
 
31. In relation to the following TPP articles, except article 18.46, there is no 
extraordinary innovation to the international patent system, regarding patents 
application, publication (“disclosure”, 18 months until the presentation date or, if given 
priority, until that earlier date of priority) and to the information that should contains 
mentioned publication. 
 
32. Patent term adjustment for unreasonable granting authority delays. Article 18.46 
introduces a patent term adjustment for unreasonable granting authority delays, which 
woke up antagonisms. This adjustment, concretized for pharmaceutical products in art. 
18.48, provides an extension of the patent protection for unreasonable or unnecessary 
delays, which we will study afterwards and doesn’t appear in TRIPS neither. 
 
33. Protection for undisclosed test or other data. In addition, it provides, as I will 
analyse later protection for undisclosed tests or other data. 
 
34. Measures relating to the marketing of certain pharmaceutical products. In article 
18.53, without any controversy, the TPP introduces different measurements relative to 
entry into the market of pharmaceutical products through which parties should establish 
mechanisms that could solve conflicts that emerge due to the authorization of 
commercialization in another party’s territory when the person is another than those 
who made the original application. 
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DISADVANTAGES OF ITS EMMERGENCE. WHY IS THE 
TPP AGREEMENT BEING CRITISIZED?  
 
35. The Trans Pacific Partnership is criticized because it doesn’t protect anymore the 
economic welfare through the entry of generic medicines, quite the opposite, 
consolidating neoliberal politics and multinational pharmaceutical interests.  
Therefore, we are facing three probable mechanisms or instruments which could extend 
the patent term, or if we want, a temporal protection of the pharmaceutical components 
or products, stopping an earlier entry for generics into the market: 1) the extension of 
patentable subjects’ matter; 2) patent term adjustment for unreasonable authority delays 
in granting; and 3) protection of undisclosed test or other data. 
1) The article 18.37.2 relative to the extension of patentable subjects’ matter to new 
uses of the known product; new methods for the known product; and new processes 
use for the known product. In some countries that could be an innovation, but 
regarding the pharmaceutical patent system of other signer countries, they establish 
in their own internal patent law term extensions by, mainly, three kind of factors: a) 
development of new product’s indication; b) development of new administration 
ways; c) development of a likely drug’s association. Consequently, this point of 
view could be in detriment of some countries, but I don’t consider it is a relevant 
measure because even if that could extend the patent’s term, it is an inventive 
activity which justifies the extension. 
2) The second source of probable issues is article 18.48 concerning to the patent term 
adjustment for unreasonable authority delays in granting. In this case, the 
adjustment comes from unjustified delays in the commercial authorization, which 
would cause the right holder a diminution of the effective patent term. 
3) Thirdly, article 18.50 relating to the protection of undisclosed tests or other data. 
This assumption even though it could have an influence on the public availability of 
information concerning determined drugs, is substantially different of the patent 
term, as we will explain later. 
 
36. Our TPP establishes that one condition to grant a commercial authorization for a 
new pharmaceutical product is the presentation of data, tests or evidences which were 
not divulgated previously according to the security or the efficacy of a product. The 
party which grants the commercial authorization, accomplished that condition, couldn’t 
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allow to third parties to access to information based on: a) mentioned information; b) 
commercial authorization granted to the person that presented the information by, at 
least, five years until the commercial authorization date of the new pharmaceutical 
product in a party’s territory. Something similar is established in case one party takes a 
valid presentation of a previous authorization of the product from another territory. The 
same article, in its second paragraph foresees: 
a) It should be established in the mentioned protection, mutatis mutandis, for a period 
never less to three years regarding new clinical information presented being required 
to support the commercial authorization of a pharmaceutical product previously 
approved covering a new indication, new formulation or another administration 
method; or alternately. 
b) Apply as well paragraph 1, mutatis mutandis, for a period never less than five years 
to a new pharmaceutical product that contains a chemical principle that hasn’t been 
approved before by the party. In this case, we are facing a dispositive rule, because 
one party can protect only tests or other data which were not divulgated concerning 
the security or efficacy relative to a chemical principle that hasn’t been approved 
before. 
 
37. Nevertheless, the polemic doesn’t arise simply by its application, but because of 
its application in countries that have different development levels, and consequently, 
don’t have the same capacity to access to the medicines. This produces that the 
measurements which could be adapted to developed countries, impede the entry of the 
drugs to countries with a low development level because of the tardive appearance of 
the generics. Until the emergence of generics success, there is a great increase of prices 
because of the monopoly of the owners of the patents, making difficult to the public 
without economic resources to access the sanitary product. For a better comprehension 
of the conflictive applicability points established previously, we will analyse the steps to 
follow starting from the application for the patent until its commercialisation, the 
pharmaceutical generics treatment, and the distinction among the “protection for 
undisclosed test or other data” and the patent. 
 
 
 
Final Degree Project                                           Author: Rubén CANO PÉREZ 
Law and Business Administration Degree                            Academic Supervisor: Manuel DESANTES REAL 
21	
	
Life cycle of a pharmaceutical product 
 
38. This cycle is normally divided in ten big periods that in several occasions can 
overlap each other: 
1) Development period in which, through basic investigation, the aim is to try to find 
and identify new therapeutic targets. 
2) The chemical synthesis of new molecules with possibility to patent and its sieving 
on likely therapeutically targets, where the objective is to be able to select some 
leader molecules.  
3) The preclinical development of new drugs, that is the period in which the study of 
biological activities begins, as many “in vitro” models as in experimental animals; 
also it is at this moment in which there is an entire consolidation of preclinical 
documentation. With this documentation, together with the development of the 
clinical plan (DCP), serves as a base to obtain the authorization, by the regulatory 
authorities, to start clinical investigation. The international normative that regulates 
preclinical investigation is described in good laboratory practices (GLP). The results 
of the preclinical tests can also be used to determinate which is the best 
pharmaceutical way that could be employed with the new drug during the clinical 
period. Once preclinical studies are completed, thousands of leading molecules are 
gradually reduced to a few medicine candidates and put to clinical development. 
Before starting clinical development periods, it is necessary, on one hand, to 
introduce all the chemical, preclinical and pharmaceutical knowledge of the 
candidate drug into a preclinical dossier; and on the other hand, to prepare the DCP 
describing all the clinical tests that would be experimented on human beings before 
applying for commercialisation. That dossier, the DCP and the investigation manual 
will be remitted to the sanitary authorities for evaluation and approval to the start 
off clinical investigation in human beings, always with known and enough 
information of the candidate drug.  
4) Clinical development of new medicines is a period in which the first clinical tests in 
humans and evaluation of the efficacy and security of the new pharmaceutical 
product under investigation takes place, but they are also tested for new uses or 
even new kinds of administration. 
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5) Later, is the period for developing integration of chemical-pharmaceutical –clinical 
or preclinical- documentation, as well as the registration and authorization by the 
corresponding agencies that regulate the commercialization of the new drug. Only a 
few medicines in this period reach this last step of development, previous to 
commercialisation, called the “registration of new drug”. That documentation called 
“register dossier” is remitted to the principal sanitary authorities –FDA (U.S), or 
EMEA and national agencies depending the procedure chosen (Europe). Once the 
dossier is evaluated by the respective regulatory agencies, in positive cases, we can 
obtain the authorization for commercialisation and consequently, the approval of the 
technical factsheet, which contains information about the new pharmaceutical 
product addressed to the sanitary professionals and the pharmaceutical leaflets, 
directed to patients and their families. 
6)  Afterwards, a certain type of documentation is needed and also a certain amount of 
time to achieve the prices authorization and reimbursements for the new medicine 
by the national sanitary authorities. If the first major milestone was the authorization 
of commercialisation and, with it, the technical factsheet and the pharmaceutical 
leaflet; the authorization of the price and reimbursement is the second biggest step 
that a drug finds on the path to access to the category of therapeutic innovation. 
Only those that are considerate as such, reach a superior price than the therapeutic 
alternatives already commercialized. 
7) The beginning of the commercialisation of new medicines and their use as a 
therapeutic alternative, regarding its therapeutic and pharmaco-economic value with 
respect to the other therapies considered standard. 
8) The therapeutic maturity of a pharmaceutical product is the period in which the 
medicine can reach the status of standard therapy. 
9) The patent expiration term, loss of exclusivity and the entry into the market of the 
generic products –apart from possible extensions due to the “not disclosure” of data 
stablished administratively-. 
10) Therapeutic obsolescence of the drug18. 
 
 
																																								 																				
18 	HERNÁNDEZ, G. :”Tratado de medicina farmacéutica”, en Editorial Panamericana, 
Madrid, 2011.	
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39. Therefore, there are two juridical basic steps in the product cycle of life: patent 
granting and the authorization for commercialisation. 
The patent term, generally, is twenty years, and regarding the TPP, can be implemented 
by the adjustments that could be made because of unreasonable delays in commercial 
authorization. Completed this authorization, other protection could start by each 
government: the protection of the test data or others information, which the 
administration grant if the applicant proves the validity and efficiency of the patented 
product. This “secondary” protection, at least five years, can be implemented if the 
circumstances require it, being overlapped most of times with the patent term, being 
absorbed or overpassed. 
 
 
Protection of undisclosed test or other data 
 
40. Unlike patents, protection of undisclosed test or other data awards exclusive 
rights of commercial nature on registered inventions and, therefore, unfold their effects 
in the market. Data exclusivity has as a primordial objective as to the existence of 
secure, effective and quality drugs, being correctly identified with appropriate 
information. 19  To achieve the protection, among other measurements it is required 
public intervention, submitting the pharmaceutical products commercialization under 
sanitary authorization and previous register. Curiously, Public Administration describes 
as well the criteria that potential applicants must follow in the evaluation process 
previous to the authorization to the pharmaceutical speciality for checking what can be 
introduced into the market.20 
 
41. The exclusive data term comes after the authorization of commercialisation even 
though the patent protection application hasn’t been made, as consequence, different 
fields or spheres of protection are permitted for the inventions. In the United States, the 
period for data protection is established in twelve years, even though the U.S. 
parliament is working on an amendment, which could be approved this year, reducing 
mentioned period to seven years. In short, data exclusivity is a concept only applied to 
																																								 																				
19 Informe técnico MSF: “Exclusividad de Datos en los Tratados Internacionales de Comercio: 
¿Qué consecuencias tienen para el acceso a los medicamentos?, 2004. 
20  CORREA, C.: “Protección de Datos presentados para el Registro de Productos 
Farmacéuticos: Implementación de las Normas del Acuerdo TRIPS”, South Centre, 2002. 
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drugs and it is defined as the period that guarantees data security and efficiency 
generated for the register and authorization of the original product. That data can’t be 
used by other people and no other essentially similar product can be allowed by the 
authorities. Data exclusivity differs to the patent’s right mainly in following aspects of 
protection. Data exclusivity: a) is not an intellectual property title granted to the 
inventor; b) is not linked to the patent or depends on it; c) does not give protection to 
the pharmaceutical principle “per se”; and d) does not prevent that a third person, 
generating in an independent manner his own secure and efficient innovation, could 
obtain the commercialization authorization for a similar product. 
 
42. In Europe, data exclusivity is already available through the Directive 
2004/27/CE, a period known as the “8+2+1”, that is also known as the Bolar Provision 
(born in U.S.).21 Hereby, a period of data administrative protection is fixed during eight 
years in relation with pharmaceutical products, even though authorized generic drugs 
could not be commercialized until after ten years from the date of the initial medicines 
authorization22. The above mentioned Bolar Provision or regulation exception, which 
can be established perfectly in some of the TPP signer’s territory, is already foreseen in 
article 30 of TRIPS, which allows the drug producers to use the patented invention to 
obtain the authorization for commercialisation of this product without the corresponding 
holder’s permission and before the patent’s term expires23. The generic pharmaceutical 
products could be commercialized as their own version of the original drug as soon as 
the patent term finishes. That immerge us into the next point. 
 
	
																																								 																				
21  VIDAL-QUADRAS, M., SAURI, O.: “Derecho de Patente, Exclusividad de Datos y 
Comercialización de Genéricos. Uso Experimental y Cláusula Bolar”, pags. 131-158, 2008. 
(Vid:http://libros-revistas-derecho.vlex.es/vid/exclusividad-genericos-experimental-bolar-
450154). 
22 Eight years are about data protection. Ten years are about commercialisation protection or 
monopoly. Therefore, finished the data protection, eight years, “generic developers” could 
access to the information to create the generic drugs, but they may not have access to the 
commercialisation. Hereby, “generic developers” have three years to create their product with 
data disclosure.     
23 SEGURA, P. : «Incertidumbres sobre patentes químico-farmacéuticas en España», en 
Jornadas de estudio y actualización en materia de patentes “Los Lunes de Patentes”, OEPM, 
Madrid, 2006. 
(Vid:http://www.ub.edu/centredepatents/pdf/doc_dilluns_CP/segura_incertidumbrespatquimfar
m.pdf) 
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Treatment of generic pharmaceutical products. 
 
43. A generic medicine is defined, basically, for being one which presents the same 
pharmaceutical form, and has an equal qualitative and quantitative composition in 
pharmacologically active substances to another that is considered the original drug, 
being a referent medicine and whose security and efficiency profile has been established 
enough by its continuous clinical use; and in addition, has demonstrated that its 
therapeutically equivalent to the referent medicine through the required bioequivalence 
studies. 
 
44. Therefore, and regarding the TPP agreement for the entry into the market 
generic drugs, we can establish the following limits: a) the pharmaceutical patent of the 
original product, which has a term of 20 years, adding the adjustments for unreasonable 
delays that could have existed in the application process for commercialisation. b) and 
data exclusivity period applicable to the reference medicaments, (5+3) (which 
pragmatically, really can operate when the patent term has expired). 
 
45. On the other hand, with independence of established periods according to the 
rules about data exclusivity, the patent has as a principal effect that the generic drug, 
which uses patented technology, can’t enter into the market until the exclusive right had 
expired. In contrary, it could be object of legal procedures by patent violation. In fact, it 
normally occurs that in this field a special litigiousness derives from the right’s holder 
interests. 
 
46. Consequently, even if the data exclusivity period is passed, the generic drug will 
not be able to be sold if it uses a technology which is under patent protection. Likewise, 
even if the patent protection doesn’t exist, it will be not possible to grant an 
authorization for a generic pharmaceutical product regarding another one, if previously 
has not passed the perceptive time established by the applicable pharmaceutical 
regulation.  
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CONCLUSION. THE MORE THINGS CHANGE THE MORE 
THEY STAY THE SAME?   
 
47. “Cambiare tutto per non cambiare nulla?”24. In this case I’m not using the 
lampedusian question to refer to the same movement which was criticized by the Italian 
writer, but it is interesting to analyse if, in all honesty, the Trans-Pacific Partnership 
brings us significant changes in relation with generic products. A report from the UN’s 
agency over AIDS (UNAIDS) has been reminding us via a communication that, in the 
Political Declaration about VIH and AIDS of 2011 “approved by unanimity by the 
General Assembly of United Nations”, the governments reiterated their engagement of 
making use of the flexible mechanisms foreseen in the TRIPS agreements, headed 
specifically to promote the access to drugs for people and their commercialization. 
Likewise, UNAIDS has affirmed, “the governments engaged to guarantee that the 
provisions about intellectual property rights contents in the trade agreements don’t be 
opposite to mentioned agreements, as well as the contents in the Doha’s Declaration 
about the TRIPS Agreement and Public Health”25. In spite of it (UNAIDS regretted) 
several trade agreements which were in negotiation declaring that “it is feared that could 
conclude the measures called TRIPS in order to implement patentability criteria and 
terms. These provisions could make it difficult for the generic concurrence and create a 
rise in drug prices. In the same way, preoccupation exists on the influence that the TPP 
could have on another future trade agreement”. 
 
48. In this case, we could be facing a modification that harms the generic 
pharmaceutical products industry, with: 
a) The adjustment established in the treaty for the possible (or probable) delays, as there 
are low developed countries in which these drugs are not foreseen, something that will 
produce a delay for the entry of the generic drug into their respective markets.  
b) Another innovation that could harm developing countries is the implementation of 
patentable subjects settling, which implies that new uses, methods or use process of 
known products can be patented. Even though, in a similar way, it could have been 
																																								 																				
24 DI LAMPEDUSA, T: “Il Gattopardo”, 1958 
25	Vid.: 
http://www.unaids.org/sites/default/files/media_asset/JC2260_DOHA+10TRIPS_en_0.pdf	
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established in some developed countries, is not the same situation for developing 
countries.  
c) Other dark point in the TPP is that in article 18.44 according to the publication of 
patent application, doesn’t introduce the “best mode”, but I understand that this doesn’t 
imply no bigger problem because all TPP signer countries are already under the TRIPS 
umbrella and in article 29.1 we can find set this requirement. Consequently, it should be 
adopted without any problem. 
d) With reference to “exclusivity”, that at the beginning of the agreement’s negotiation 
was filtered that U.S. wanted to set a 12-year period of data protection, has finally been 
fixed in the “5+3 mechanism”. I don’t believe that this last point is going to have great 
importance, because usually (if not always) every new pharmaceutical product is 
already protected by a patent, which normally will expire later than data protection 
which different governments could provide26. 
 
49. Therefore, bearing in mind what I wrote before, I would wish to highlight that 
this agreement can’t be regarded as the beginning of the apocalypse for people from 
developing countries. While it is true that the two new provisions, which I mentioned 
before, can postpone generic drugs apparition, it is not a situation that changes 
extraordinarily the previous scenario, which comes mostly from the TRIPS agreement, 
and when developing countries subscribed it27. In all signer’s countries (of the TPP) the 
pharmaceutical patent was already settled at 20 years, because those countries had 
already signed TRIPS, and are not being considered (none of the TPP subscribers) as 
least developed countries. So, the provisions for least developed countries that Doha’s 
Round Declaration of 2001 about TRIPS and Public Health foresees can’t be applied 
for pharmaceutical products in those countries28. 
 
																																								 																				
26	KANTARJIAN, H.: «Strategies that Delay or Prevent the Timely Availability of Affordable 
Generic Drugs in the United States», American Society of Hematology, New York, 2016. 
27 SYKES, A. : «TRIPS, Pharmaceuticals, Developing Countries, and the Doha “Solution”», 
University of Chicago, Chicago, 2001, Working Paper No. 140 (2d series). 
28 Least developed countries could have maximum flexibility at least until 2033 according to the 
the Decision of the Council on the TRIPS Agreement and Public Health, adopted on 6th 
November 2015 regarding Article 66, Paragraph. No-one of the parties signing the TPP is 
considered least developed country.  
(vid: https://www.wto.org/spanish/news_s/news15_s/trip_06nov15_s.htm). 
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50. Thus, it is being consolidated (not starting), the diminution of access to 
knowledge, which produces a significant raise on the price of essential goods and 
products, as pharmaceutical products or surgeries are. Increasing monopoly of big 
pharmaceutical enterprises in the market, we can appreciate how the WTO is not acting 
enough to find the balance between public and private interest again, which could 
satisfy more efficiently the whole population. 
 
51. For developing countries, for those who are not protected by the WTO with the 
mentioned provision for least developed countries, the only benefit that I can appreciate 
is the access to the database of some patents when the patent term has expired. Not 
beyond at all of the reality, and such a relevant decision, the reasonable position should 
be: a) increase (not restrict) the access to the knowledge; and b) avoid the patent term 
extension at the end of its protection. 
Hereby, it is confirmed the theory mentioned at the beginning of the TPP analysis, 
which shows that the situation regarding different level of development in different 
countries is not a direct consequence of the TPP but the result of the failure by all the 
international organisms of trying to protect least (or low) developed countries. 
 
52. To conclude, the TPP establishes several measurements that, to the choice of 
each country, could implement the protection term patents in a different way, and 
without doubts could contribute to the delay of the generic access to people. What 
cannot be allowed is the trends which manifest that the starting point of inequality is 
this treaty. It is result of the little willingness of developed countries to concede some 
measurements to developing countries and their needs for their own evolution. As well, 
continuing on this approach but without talking about legislative issues that could 
present those agreements for the social welfare, we find a large number of “extra-
borders” activities, and concretely, the role that lobbies play on it.  Those groups of 
pressure, pharmaceutical in this case, decided to exercise a voracious incidence on the 
TPP negotiations, pressing the U.S., and as it could be expected in our neoliberal 
system, pointing out the way to follow for the legal redaction and interpretation. 
Therefore, in my opinion, the redaction of the TPP (in the big picture but always 
keeping the mesenteries of the subject under the directives marked by U.S.) hides the 
pharmaceutical enterprises interests, and their principal representatives, under lobbies. 
That, in a certain way, broke the balance (which already doesn’t exist), among the 
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public interest and big pharmaceutical enterprises interests, inclined (this hypothetical 
balance) to the private operators. 
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